Low-Dose Aspirin
Episodes covering low-dose aspirin — protocols, research, and expert discussions.
Daily low-dose aspirin (75-100mg) for cardiovascular protection and cancer prevention, with important age and weight considerations.
Low-dose aspirin is one of the most studied OTC interventions with proven cardiovascular benefits and emerging cancer prevention data. However, recent guideline changes have made it more nuanced, it's no longer recommended for everyone.
The evidence is strong for:
- Reducing heart attacks and strokes in high-risk individuals (40-59)
- Colorectal cancer prevention (55% reduction in recurrence in 2025 data)
- Anti-inflammatory effects via NF-κB and COX-2 suppression
The caveats are significant:
- Not recommended to START in adults 60+ (bleeding risk outweighs benefit)
- Low-dose (75-100mg) works best for people under 70kg
- Bleeding risk (GI and intracranial) increases with age
- ASPREE trial showed possible increased advanced cancer risk in 70+
If you're 40-59 with elevated cardiovascular risk and weigh under 70kg, low-dose aspirin may offer meaningful protection. For others, the risk/benefit calculation is less favorable. Always discuss with your doctor, this is not a supplement to take casually.
Science & Mechanisms
Mechanisms of Action
Aspirin (acetylsalicylic acid) works through multiple pathways:
COX Inhibition:
- Irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2
- Reduces thromboxane A2 production → anti-platelet effect
- Reduces prostaglandin synthesis → anti-inflammatory
NF-κB Suppression:
- Inhibits nuclear factor kappa-B activation
- Suppresses downstream inflammatory genes (COX-2, iNOS, VCAM-1, ICAM-1)
- Blocks phosphorylation of IκBα
Antioxidant Effects:
- Reduces reactive oxygen species
- Inhibits nuclear translocation of thioredoxin
- May reduce oxidative damage associated with aging
Cancer Prevention Mechanisms:
- COX-2 inhibition reduces tumor-promoting prostaglandins
- Anti-platelet effect may reduce metastatic spread
- Direct effects on cell proliferation pathways
- Strongest evidence for colorectal cancer
The Weight Factor
A landmark 2018 Lancet analysis revealed that body weight significantly affects aspirin efficacy:
| Weight | Low-Dose (75-100mg) Benefit |
|---|---|
| 50-69 kg | Substantial CVD reduction |
| 70+ kg | No significant benefit |
| 70+ kg | Increased case fatality |
Higher doses (300-325mg) may be needed for heavier individuals, but this increases bleeding risk.
Age Considerations
The risk/benefit ratio shifts dramatically with age:
- Under 40: Generally not recommended (low baseline risk)
- 40-59: Consider if 10-year CVD risk ≥10%
- 60-69: Weaker recommendation, individual decision
- 70+: Generally NOT recommended to initiate (USPSTF 2022)
The ASPREE trial (19,114 adults 70+) found daily low-dose aspirin did not prolong healthy survival and was associated with increased bleeding and possibly higher cancer mortality.
Episodes
Most drugs bind to 20-30 proteins but are only approved for one use, leaving massive therapeutic potential untapped. Aspirin cuts colon cancer recurrence; lidocaine before breas...
Dr. Ronald Hoffman and nutritionist Leyla Muedin discuss a listener question about criteria for prescribing daily low-dose aspirin. They explain that aspirin was once recommende...
Dr. Chapa reviews the latest evidence on low-dose aspirin therapy in pregnancy, focusing on an upcoming clinical opinion in the American Journal of OBGYN. The episode traces the...
JAMA Editor Howard Bauchner interviews Dr. Randall Stafford, a professor of medicine at Stanford, about his viewpoint on navigating the shifting landscape of low-dose aspirin fo...
Dr. Chapa reviews a new expert review from AJOG MFM (November 2024) arguing that 162 mg aspirin is superior to 81 mg for preeclampsia prophylaxis. He traces the accumulating evi...
Dr. Bob Centor interviews hematologist Dr. Zoe McQuilton about her secondary analysis of the ASPREE trial examining how daily low-dose aspirin affects iron status and anemia ris...
JAMA Associate Editor Dr. Linda Brubaker interviews Dr. Erin Coy, a USPSTF member and professor at Oregon Health and Science University, about the updated Task Force recommendat...
Dr. Chapa reviews the ASPIRIN trial published in The Lancet (January 2020) examining whether low-dose aspirin can reduce preterm birth in nulliparous women. This multi-country, ...